CONTENTS

Advances in Brief


3199 Reversible, p16-mediated Cell Cycle Arrest as Protection from Chemotherapy. Steven Stone, Priya Dayanand, and Alexander Kamb.

3203 Fluoropyrimidine-mediated Radiosensitization Depends on Cyclin E-dependent Kinase Activation. Theodore S. Lawrence, Mary A. Davis, and Tania L. Loney.

3207 Alternate Splicing of the r75 Gene Product and Its Overexpression in a 5-Fluorouracil-resistant Cell Line. Bruce J. Dolnick and Adrian R. Black.

3211 Tumor Necrosis Factor α-induced Vascular Leakage Involves PECAM1 Phosphorylation. Elisabeta Ferrero, Antonello Villa, Maria Elena Ferrero, Elisabeta Toninelli, Jeffrey R. Bender, Ruggero Pardi, and Maria Raffaella Zocchi.


3230 DNA Copy Number Losses in Chromosome 14: An Early Change in Gastrointestinal Stromal Tumors. Wa’el El-Rifai, Maarit Sarlomo-Rikala, Markku Miettinen, Sakari Knuttila, and Leif C. Andersson.

3234 Complex Cadherin Expression in Renal Cell Carcinoma. Toru Shimazui, Laurence A. Giroldi, Pierre Paul Bringuier, Egbert Oosterwijk, and Jack A. Schalke.

Regular Articles

Carcinogenesis


3244 Targeted Expression of Human O6-Methylguanine-DNA Methyltransferase (MGMT) in Transgenic Mice Protects against Tumor Initiation in Two-Stage Skin Carcinogenesis. Klaus Becker, Jörg Dosch, Cornelia M. Gregel, Brian A. Martin, and Bernd Kaina.

3250 GADD153/CHOP, a DNA Damage-inducible Protein, Reduced CAAT/Enhancer Binding Protein Activities and Increased Apoptosis in 3D cl3 Myeloid Cells. Alan D. Friedman.

3257 Growth Regulation by Peroxisome Proliferators: Opposing Activities in Early and Late G1, Brian J. Ledwith, Timothy E. Johnson, Linda K. Wagner, Cindy J. Paulay, Sujata Manam, Sheila M. Galloway, and Warren W. Nichols.

3265 Regulation of Ornithine Decarboxylase in a Transformed Cell Line That Overexpresses Translation Initiation Factor eIF-4E. Lisa M. Shantz, Re-Huang Hu, and Anthony E. Pegg.


Endocrinology


Experimental Therapeutics


Characterization of angiogenic activity is measured by comparing the ratio of angiogenic stimulators (e.g. VEGF or bFGF) to angiogenic inhibitors (e.g. Endostatin). Applications include: cancer, cardiovascular disease, rheumatoid arthritis, transplant technology, and acute phase responses.

**ACCUCYTETM:**

The Accepted Standard for Measuring Angiogenic Signaling

Endogenous levels of angiogenic stimulators and inhibitors

See www.cytimmune.com for additional information.

**Molecular Biology and Genetics**


3324 Definition of a DNA Repair Domain in the Genomic Region Containing the Human p53 Gene. Dawn M. Tolbert and George J. Kantor.

3331 Semiautomated Assessment of Loss of Heterozygosity and Replication Error in Tumors. Federico Canziani, Reijo Salovaara, Akseli Hemminki, Paula Kristo, Robert B. Chadwick, Lauri A. Aaltonen, and Albert de la Chapelle.


**Tumor Biology**


3350 Involvement of Herogulin-β2 in the Acquisition of the Hormone-independent Phenotype of Breast Cancer Cells. Careen K. Tang, Cynthia Perez, Thomas Grunt, Caroline Wibbel, Cheryl Cho, and Ruth Lupu.

3359 Transforming Growth Factor β1 Stimulates Contrasting Responses in Metastatic versus Primary Mouse Prostate Cancer-derived Cell Lines in Vivo. Inder Sehgal, Patricia A. Balely, and Timothy C. Thompson.


**Special Article**


---

**3387 Announcements**

Future Annual Meetings of the AACR
1997 Annual Meeting
Call for Nominations for AACR Awards
AACR Special Conferences in Cancer Research
Calendar of Events

**3390 Author Index**

AACR forms available in the back of this issue:
Application for Active and Corresponding Membership
Application for Associate Membership

Also available in the back of this issue:
Guidelines for Submitting Disks to AACR Publications